361 related articles for article (PubMed ID: 16219165)
1. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
2. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis.
Marsman M; Jordens I; Griekspoor A; Neefjes J
Adv Cancer Res; 2005; 93():129-58. PubMed ID: 15797446
[TBL] [Abstract][Full Text] [Related]
5. HLA class II antigen presentation by prostate cancer cells.
Younger AR; Amria S; Jeffrey WA; Mahdy AE; Goldstein OG; Norris JS; Haque A
Prostate Cancer Prostatic Dis; 2008; 11(4):334-41. PubMed ID: 17938645
[TBL] [Abstract][Full Text] [Related]
6. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
7. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
[TBL] [Abstract][Full Text] [Related]
8. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
[TBL] [Abstract][Full Text] [Related]
10. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
11. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
12. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
13. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
14. Principles of tumor immunosurveillance and implications for immunotherapy.
Ochsenbein AF
Cancer Gene Ther; 2002 Dec; 9(12):1043-55. PubMed ID: 12522443
[TBL] [Abstract][Full Text] [Related]
15. Structural principles of MHC class II antigen presentation.
Nelson CA; Fremont DH
Rev Immunogenet; 1999; 1(1):47-59. PubMed ID: 11256572
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
18. MHC class I down-regulation: tumour escape from immune surveillance? (review).
BubenÃk J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]